Drugs / VAL489
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01617681 | Nov 2012 → Jan 2017 | hypertensive disorder | Novartis Pharmaceuticals | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAL489 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01617681 ↗ |